162 related articles for article (PubMed ID: 21714645)
1. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
Morrow L; Muchmore DB; Ludington EA; Vaughn DE; Hompesch M
Diabetes Technol Ther; 2011 Oct; 13(10):1039-45. PubMed ID: 21714645
[TBL] [Abstract][Full Text] [Related]
2. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
3. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.
Vaughn DE; Yocum RC; Muchmore DB; Sugarman BJ; Vick AM; Bilinsky IP; Frost GI
Diabetes Technol Ther; 2009 Jun; 11(6):345-52. PubMed ID: 19459762
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
[TBL] [Abstract][Full Text] [Related]
5. Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase.
Muchmore DB; Vaughn DE
J Diabetes Sci Technol; 2012 Jul; 6(4):764-72. PubMed ID: 22920800
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers.
Dychter SS; Harrigan R; Bahn JD; Printz MA; Sugarman BJ; DeNoia E; Haughey DB; Fellows D; Maneval DC
Clin Ther; 2014 Feb; 36(2):211-24. PubMed ID: 24486335
[TBL] [Abstract][Full Text] [Related]
7. The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers.
Thomas JR; Yocum RC; Haller MF; Flament J
J Pain Symptom Manage; 2009 Nov; 38(5):673-82. PubMed ID: 19819667
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL.
de la Peña A; Seger M; Soon D; Scott AJ; Reddy SR; Dobbins MA; Brown-Augsburger P; Linnebjerg H
Clin Pharmacol Drug Dev; 2016 Jan; 5(1):69-75. PubMed ID: 27119580
[TBL] [Abstract][Full Text] [Related]
10. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
[TBL] [Abstract][Full Text] [Related]
11. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
[TBL] [Abstract][Full Text] [Related]
12. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
[TBL] [Abstract][Full Text] [Related]
13. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers.
Harb G; Lebel F; Battikha J; Thackara JW
Curr Med Res Opin; 2010 Feb; 26(2):279-88. PubMed ID: 19947907
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects.
Leohr J; Dellva MA; LaBell E; Coutant DE; Klein O; Plum-Moerschel L; Zijlstra E; Linnebjerg H
Clin Ther; 2020 Sep; 42(9):1762-1777.e4. PubMed ID: 32900535
[TBL] [Abstract][Full Text] [Related]
16. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness.
Thomas JR; Wallace MS; Yocum RC; Vaughn DE; Haller MF; Flament J
J Pain Symptom Manage; 2009 Nov; 38(5):663-72. PubMed ID: 19819665
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
18. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
[TBL] [Abstract][Full Text] [Related]
19. Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.
Vaughn DE; Muchmore DB
Endocr Pract; 2011; 17(6):914-21. PubMed ID: 22138081
[TBL] [Abstract][Full Text] [Related]
20. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Vaughn DE
Diabetes Care; 2011 Mar; 34(3):666-8. PubMed ID: 21273493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]